Physician profile
Samuela Manages
NPI 1750549044
$1,238.63
in general payments reported to CMS, 2019-2025
15 companies · $83.89 in 2025
The $83.89 reported for 2025 was less than what a typical Addiction Medicine (Family Medicine) provider received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $95.30 · 2022: $12.85 · 2023: $79.56 · 2024: $545 · 2025: $83.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $199.62 | 2023-2025 | Brixadi |
| Pfizer INC. | $184.09 | 2019-2024 | |
| Gilead Sciences, INC. | $178.76 | 2019-2024 | Epclusa |
| Glaxosmithkline, LLC. | $114.59 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $105.26 | 2019-2020 | |
| Novo Nordisk INC | $93.85 | 2019-2024 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $92.63 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $86.15 | 2019-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $48.98 | 2019-2022 | |
| Alkermes, INC. | $48.20 | 2024 | Aristada, Vivitrol, Lybalvi |
| Merck Sharp & Dohme LLC | $20.24 | 2024 | Vaxelis, Vaxneuvance, Gardasil |
| Madrigal Pharmaceuticals | $18.58 | 2024 | Resmetirom |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.57 | 2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $18.32 | 2019 | |
| Astellas Pharma US INC | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuela Manages listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.